Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

26.31
-0.4100-1.53%
Volume:363.58K
Turnover:9.52M
Market Cap:2.72B
PE:-7.72
High:26.47
Open:26.37
Low:25.86
Close:26.72
52wk High:28.23
52wk Low:8.20
Shares:103.41M
Float Shares:95.05M
Volume Ratio:0.53
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:6.76
PE(LYR):-8.62

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and Incyte (INCY)

TIPRANKS
·
Jun 09

Nurix Therapeutics price target raised to $45 from $41 at Jefferies

TIPRANKS
·
Jun 09

Nurix Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Jun 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 08

Nurix Therapeutics Inc : Needham Raises Target Price to $34 From $26

THOMSON REUTERS
·
Jun 08

Nurix Therapeutics downgraded to Equal Weight at Wells Fargo after Roche deal

TIPRANKS
·
Jun 08

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Benzinga
·
Jun 08

BUZZ-U.S. STOCKS ON THE MOVE-Campbell's, VinFast, Corning

Reuters
·
Jun 08

Futures Point Higher as Tech and Space Shares Recover After Sharp Sell-Off

Deep News
·
Jun 08

US Stock Futures Rise Ahead of Key Week; Chip and Space Stocks Rebound; Iran Halts Military Action

Stock News
·
Jun 08

BUZZ-U.S. STOCKS ON THE MOVE-Marvell, Nvidia, Broadcom

Reuters
·
Jun 08

Nurix Therapeutics teams with Roche to develop, commercialize bexobrutideg

TIPRANKS
·
Jun 08

Nurix Therapeutics Soars in Premarket on Roche's $2.3 Billion Deal for Blood Cancer Drug Rights

Stock News
·
Jun 08

Nurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche

Reuters
·
Jun 08

Shares of Nurix Therapeutics up 57.1% Premarket After $2 Bln Cancer Drug Agreement With Roche

THOMSON REUTERS
·
Jun 08

Roche enters $2 billion cancer drug agreement with Nurix Therapeutics

Reuters
·
Jun 08

PRESS DIGEST -Wall Street Journal - June 8

Reuters
·
Jun 08

Roche To Collaborate With Nurix Therapeutics On BTK Degrader Bexobrutideg

Reuters
·
Jun 08

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

GlobeNewswire
·
Jun 08

Nurix Therapeutics Chief Legal Officer Christine Ring sells 8,148 shares for $135,226.72

Reuters
·
Jun 03